In a 67‑kg patient with type 2 diabetes who is 3 days post‑kidney transplant, has creatinine 4.24 mg/dL (eGFR ≈10 mL/min) and a fasting blood glucose of 230 mg/dL, what should the initial insulin glargine (Lantus) dose, insulin‑to‑carbohydrate ratio, and insulin sensitivity factor be?

Insulin Dosing in Post-Kidney Transplant Patient with Severe Renal Dysfunction

Start Lantus at 10 units once daily (0.15 units/kg), use an insulin-to-carbohydrate ratio of 1:15, and an insulin sensitivity factor of 1:50, with aggressive daily titration and close monitoring for hypoglycemia given the severe renal impairment.

Lantus (Basal Insulin) Dosing

Initial dose: 10 units once daily 1. The FDA label for Lantus explicitly recommends 10 units (or 0.2 units/kg) as the starting dose for type 2 diabetes patients not currently on insulin 1. However, given this patient's severe renal dysfunction (eGFR 10 mL/min), I recommend starting conservatively at 10 units (approximately 0.15 units/kg) rather than the full 0.2 units/kg to minimize hypoglycemia risk.

Key Considerations for Renal Impairment:

• Severe CKD (Stage 5) substantially increases hypoglycemia risk due to reduced insulin clearance and impaired gluconeogenesis 2
• This patient meets multiple high-risk criteria: eGFR <60, likely age ≥65, and acute post-transplant stress 2
• Paradoxically, patients with renal failure may require higher basal insulin doses to achieve target glucose levels 3, but initial dosing must be conservative
• Insulin glargine has demonstrated safety across all CKD stages with low severe hypoglycemia rates (0.04%/patient-year in Stage 4-5 CKD) 4

Titration Algorithm:

Adjust daily based on fasting glucose using this structured approach 5:

• If FBG ≥180 mg/dL (≥10 mmol/L): increase by 6-8 units
• If FBG 140-179 mg/dL (7.8-9.9 mmol/L): increase by 4 units
• If FBG 120-139 mg/dL (6.7-7.7 mmol/L): increase by 2 units
• If FBG 100-119 mg/dL (5.6-6.6 mmol/L): increase by 0-2 units
• If FBG <100 mg/dL or any hypoglycemia: decrease by 2-4 units

Target fasting glucose: 100-140 mg/dL initially, given the high-risk profile 2, 3

Insulin-to-Carbohydrate Ratio (ICR)

Start with 1:15 ratio (1 unit of rapid-acting insulin per 15 grams of carbohydrate).

Rationale:

• Standard "500 rule" calculation: 500 ÷ total daily dose (TDD)
• Estimated TDD for this patient: 30-40 units (basal 10 units + prandial coverage)
• 500 ÷ 35 = approximately 1:14-15
• Use 1:15 conservatively given severe renal impairment and hypoglycemia risk
• Adjust based on 2-hour postprandial glucose readings 2

Insulin Sensitivity Factor (ISF)

Start with 1:50 (1 unit of rapid-acting insulin lowers glucose by 50 mg/dL).

Rationale:

• Standard "1800 rule" for rapid-acting insulin: 1800 ÷ TDD
• 1800 ÷ 35 = approximately 1:51
• Use 1:50 conservatively to avoid overcorrection
• In severe CKD, insulin sensitivity is unpredictable due to uremia-induced insulin resistance versus reduced clearance 6

Critical Safety Considerations

Hypoglycemia Prevention:

• This patient is at extremely high risk for severe hypoglycemia 2
• Consider real-time CGM with confirmatory point-of-care glucose testing if available 2
• Check glucose before each meal and at bedtime minimum
• Hold correction insulin if glucose <120 mg/dL pre-meal initially
• Educate on hypoglycemia recognition and treatment

Post-Transplant Specific Issues:

• Immunosuppression (tacrolimus, corticosteroids) will worsen hyperglycemia 6
• Expect insulin requirements to increase as steroid doses remain high
• Post-transplant diabetes mellitus (PTDM) affects 7-39% of kidney transplant recipients 6
• Tacrolimus levels should be kept <10 ng/mL when possible to reduce diabetogenic effects 6

Monitoring Requirements:

• Daily glucose monitoring at minimum: fasting, pre-meals, bedtime, and 3 AM initially
• Adjust insulin doses daily during hospitalization based on patterns 7, 1
• Recheck renal function frequently as improving GFR will increase insulin clearance
• HbA1c of 230 mg/dL suggests poor baseline control; expect HbA1c >8% 3

Medication Reconciliation:

• Discontinue metformin (contraindicated at eGFR <30) 8
• Avoid sulfonylureas (severe hypoglycemia risk in renal failure)
• Consider SGLT2 inhibitors once eGFR improves >20-25 mL/min for cardio-renal protection 8, 9
• GLP-1 receptor agonists may be considered but require dose adjustment in severe CKD 8

Structured Discharge Planning

Per 2025 ADA guidelines, ensure 7:

• Diabetes self-management education before discharge
• Medication reconciliation with attention to access
• Follow-up within 1-2 weeks (not 1 month) given active insulin titration and high-risk status
• Clear hypoglycemia action plan
• Glucose monitoring supplies and insulin delivery devices

This regimen prioritizes safety over aggressive glycemic control in the immediate post-transplant period, recognizing that severe hypoglycemia poses greater immediate mortality risk than transient hyperglycemia in this critically vulnerable patient.